A Phase 1 interventional study of Belbuca 300 µg and Belbuca 600 µg in Respiratory Depression, sponsored by BioDelivery Sciences International. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-05.
Sponsored by BioDelivery Sciences International · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 349 studies in Respiratory Insufficiency with a site in United States — 44 open to participants now, 60 under way, 1 of them phase 3. Respiratory Insufficiency · United States.
Among the 349 studies in Respiratory Insufficiency with a site in United States, this one is the 182nd largest by enrollment of the 253 interventional ones that give a count, is one of 17 that started in 2019, is one of 23 in phase 1, and was the 203rd registered.
1,370 studies on the registry are indexed under Respiratory Insufficiency; 264 are open to participants now.
Browse Respiratory Insufficiency studies →44 of the 349 studies in Respiratory Insufficiency with a site in United States are open now. Recruiting first, the newest first:
University of California, Davis · Sites in United States
Ages up to 28 days
University of Rochester · Sites in United States
Ages 18+ · Healthy volunteers
Thomas Jefferson University · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 1 days–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
349 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 42 · Phase 3 27 · Phase 4 9
First in 1992; this study’s year is marked. 17 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 60 across 860 interventional studies indexed under Respiratory Insufficiency.
Median enrollment 42 across the 253 interventional studies, 65 across the 95 observational. Of the 246 that completed or were terminated, 93 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 349 have an industry lead sponsor. The 10 most frequent:
BioDelivery Sciences International is the lead sponsor of 21 studies on the registry; 1 is open to participants now.
BioDelivery Sciences International has 2 studies filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
24 of the studies in Respiratory Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217197Thomas Jefferson UniversityRespiratory Monitoring System That Detects & Predicts OIRD | 2026-11-30 |
| NCT04664192Baylor Research InstituteBio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research | 2026-12-01 |
| NCT05462600University of California, San DiegoDistribution of Ventilation, Respiratory Drive and Gas Exchange: Measurements and Monitoring | 2026-12-30 |
| NCT05893420AgileMD, Inc.A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning | 2026-12-31 |
| NCT06938217Institute for Extracorporeal Life SupportSafety and Efficacy of Low-Flow ECMO in a Multi-modal Cohort of Adults in Respiratory Failure | 2026-12-31 |
Add all 24 to your calendar (.ics) → With an account.
Among the 349 studies in Respiratory Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to explore and compare VRH after administration of Belbuca, Oxycodone HCl and Placebo in recreational opioid users. This is a single-center, double -blind, double-dummy , placebo-controlled randomized crossover study in up to 18 men and women self identifying as recreational users. This study will consist of a screening phase, treatment phase (which includes the Naloxone Challenge test) and follow-up visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
Drug: Belbuca 300 µg
Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
Drug: Belbuca 600 µg
Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
Drug: Belbuca 900 µg
Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
Drug: Oxycodone 30 mg
Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
Drug: Oxycodone 60 mg
Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
Drug: Placebo
Belbuca 300 µg buccal film
Belbuca 600 µg buccal film
Belbuca 900 µg buccal film
Oxycodone 30 mg capsule
Oxycodone 60 mg capsule
placebo buccal film and oral placebo
Respiratory Drive
Respiratory drive was evaluated by measuring the Ventilatory Response to Hypercapnia (VRH) through assessment of the maximum decrease (Emax) in minute ventilation (mL/min) after administration of Belbuca, Oxycodone hydrochloride, and placebo.
Time frame: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3 and 4 hours
Pupil Diameter
Pupil diameter will be assessed by pupillometry predose and at multiple timepoints after completion of Belbuca, oxycodone hydrochloride, and placebo dosing.
Time frame: pre-dose, 0.5, 1, 1.5, 2, 2.5, 3 and 4 hours
Change in Ratio of Minute Ventilation
Change in ratio of maximum decrease (Emax) in minute ventilation (mL/min) over maximum (Emax) end-tidal carbon dioxide (CO2, mmHg) after administration of Belbuca, oxycodone hydrochloride, and placebo.
Time frame: pre-dose, 0.5, 1, 2, 2.5, 3 and 4 hours
Adverse Event (AE) Reporting of Belbuca, Oxycodone Hydrochloride and Placebo for 6 Periods.
Number of Participants with indicated Adverse Event (AE) in subjects receiving Belbuca, oxycodone hydrochloride, and placebo for 6 periods.
Time frame: 44 days
| Milestone | ABCDEF | BCDEFA | CDEFAB | DEFABC | EFABCD | FABCDE |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 3 | 3 | 3 |
| Completed | 3 | 3 | 4 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | ABCDEF | BCDEFA | CDEFAB | DEFABC | EFABCD | FABCDE |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 3 | 3 | 3 |
| Completed | 3 | 2 | 2 | 3 | 3 | 3 |
| Not completed | 0 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Positive urine drug screen | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | ABCDEF | BCDEFA | CDEFAB | DEFABC | EFABCD | FABCDE |
|---|---|---|---|---|---|---|
| Started | 3 | 2 | 2 | 3 | 3 | 3 |
| Completed | 3 | 2 | 2 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | ABCDEF | BCDEFA | CDEFAB | DEFABC | EFABCD | FABCDE |
|---|---|---|---|---|---|---|
| Started | 3 | 2 | 2 | 3 | 3 | 3 |
| Completed | 3 | 2 | 2 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | ABCDEF | BCDEFA | CDEFAB | DEFABC | EFABCD | FABCDE |
|---|---|---|---|---|---|---|
| Started | 3 | 2 | 2 | 3 | 3 | 3 |
| Completed | 3 | 2 | 2 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | ABCDEF | BCDEFA | CDEFAB | DEFABC | EFABCD | FABCDE |
|---|---|---|---|---|---|---|
| Started | 3 | 2 | 2 | 3 | 3 | 3 |
| Completed | 3 | 2 | 2 | 3 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | ABCDEF | BCDEFA | CDEFAB | DEFABC | EFABCD | FABCDE |
|---|---|---|---|---|---|---|
| Started | 3 | 2 | 2 | 3 | 2 | 3 |
| Completed | 3 | 2 | 2 | 3 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | ABCDEF | BCDEFA | CDEFAB | DEFABC | EFABCD | FABCDE |
|---|---|---|---|---|---|---|
| Started | 3 | 2 | 2 | 3 | 2 | 3 |
| Completed | 3 | 2 | 2 | 3 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | ABCDEF | BCDEFA | CDEFAB | DEFABC | EFABCD | FABCDE |
|---|---|---|---|---|---|---|
| Started | 3 | 2 | 2 | 3 | 2 | 3 |
| Completed | 3 | 2 | 2 | 3 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | ABCDEF | BCDEFA | CDEFAB | DEFABC | EFABCD | FABCDE |
|---|---|---|---|---|---|---|
| Started | 3 | 2 | 2 | 3 | 2 | 3 |
| Completed | 3 | 2 | 2 | 3 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | ABCDEF | BCDEFA | CDEFAB | DEFABC | EFABCD | FABCDE |
|---|---|---|---|---|---|---|
| Started | 3 | 2 | 2 | 3 | 2 | 3 |
| Completed | 3 | 2 | 2 | 3 | 2 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Respiratory drive was evaluated by measuring the Ventilatory Response to Hypercapnia (VRH) through assessment of the maximum decrease (Emax) in minute ventilation (mL/min) after administration of Belbuca, Oxycodone hydrochloride, and placebo.
| mL/min | Treatment A: Belbuca 300 µg and Oral Placebo | Treatment B: Belbuca 600 µg and Oral Placebo | Treatment C: Belbuca 900 µg and Oral Placebo | Treatment D: Oxycodone 30 mg and Buccal Placebo | Treatment E: Oxycodone 60 mg and Buccal Placebo | Treatment F: Oral Placebo and Buccal Placebo |
|---|---|---|---|---|---|---|
| Respiratory Drive | 23957.34 ± 5554.061 | 22460.95 ± 8957.064 | 23626.79 ± 5025.767 | 21577.15 ± 806.552 | 17223.80 ± 4486.557 | 22645.74 ± 6965.108 |
Pupil diameter will be assessed by pupillometry predose and at multiple timepoints after completion of Belbuca, oxycodone hydrochloride, and placebo dosing.
| mm | Treatment A: Belbuca 300 µg and Oral Placebo | Treatment B: Belbuca 600 µg and Oral Placebo | Treatment C: Belbuca 900 µg and Oral Placebo | Treatment D: Oxycodone 30 mg and Buccal Placebo | Treatment E: Oxycodone 60 mg and Buccal Placebo | Treatment F: Oral Placebo and Buccal Placebo |
|---|---|---|---|---|---|---|
| Predose | 4.93 ± 0.676 | 5.11 ± 1.063 | 4.91 ± 0.564 | 5.11 ± 0.922 | 4.82 ± 0.962 | 4.87 ± 1.150 |
| 0.5 hours Post | 4.65 ± 0.770 | 5.00 ± 1.020 | 4.91 ± 0.667 | 4.17 ± 1.041 | 3.48 ± 1.147 | 4.90 ± 1.041 |
| 1 hour Post | 4.49 ± 0.774 | 4.83 ± 0.973 | 4.32 ± 0.617 | 3.09 ± 0.741 | 2.77 ± 0.726 | 4.71 ± 1.091 |
| 1.5 hours Post | 4.42 ± 0.833 | 4.45 ± 0.838 | 3.85 ± 0.412 | 3.16 ± 0.693 | 2.81 ± 0.798 | 4.75 ± 1.127 |
| 2 hours Post | 3.89 ± 0.703 | 3.80 ± 0.698 | 3.27 ± 0.476 | 3.17 ± 0.721 | 2.7 ± 0.633 | 4.65 ± 0.952 |
| 2.5 hours Post | 3.87 ± 0.736 | 3.56 ± 0.676 | 3.15 ± 0.517 | 3.31 ± 0.688 | 2.87 ± 0.728 | 4.89 ± 1.033 |
| 3 hours Post | 3.67 ± 0.732 | 3.31 ± 0.688 | 2.99 ± 0.548 | 3.28 ± 0.722 | 2.82 ± 0.665 | 4.80 ± 0.963 |
| 4 hours Post | 3.57 ± 0.720 | 3.25 ± 0.625 | 2.92 ± 0.653 | 3.51 ± 0.716 | 2.90 ± 0.634 | 4.89 ± 0.903 |
Change in ratio of maximum decrease (Emax) in minute ventilation (mL/min) over maximum (Emax) end-tidal carbon dioxide (CO2, mmHg) after administration of Belbuca, oxycodone hydrochloride, and placebo.
| ratio | Treatment A: Belbuca 300 µg and Oral Placebo | Treatment B: Belbuca 600 µg and Oral Placebo | Treatment C: Belbuca 900 µg and Oral Placebo | Treatment D: Oxycodone 30 mg and Buccal Placebo | Treatment E: Oxycodone 60 mg and Buccal Placebo | Treatment F: Oral Placebo and Buccal Placebo |
|---|---|---|---|---|---|---|
| Change in Ratio of Minute Ventilation | 591.74 ± 135.568 | 536.28 ± 195.123 | 576.76 ± 115.782 | 518.81 ± 162.565 | 411.88 ± 100.259 | 546.09 ± 179.371 |
Number of Participants with indicated Adverse Event (AE) in subjects receiving Belbuca, oxycodone hydrochloride, and placebo for 6 periods.
| participants | Treatment A: Belbuca 300 µg and Oral Placebo | Treatment B: Belbuca 600 µg and Oral Placebo | Treatment C: Belbuca 900 µg and Oral Placebo | Treatment D: Oxycodone 30 mg and Buccal Placebo | Treatment E: Oxycodone 60 mg and Buccal Placebo | Treatment F: Oral Placebo and Buccal Placebo |
|---|---|---|---|---|---|---|
| Mild | 7 | 11 | 10 | 8 | 12 | 2 |
| Moderate | 1 | 1 | 2 | 1 | 2 | 0 |
| Severe | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over 44 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: Belbuca 300 µg and Oral Placebo | 0/16 (0%) | 0/16 (0%) | 8/16 (50%) |
| Treatment B: Belbuca 600 µg and Oral Placebo | 0/16 (0%) | 0/16 (0%) | 12/16 (75%) |
| Treatment C: Belbuca 900 µg and Oral Placebo | 0/17 (0%) | 0/17 (0%) | 12/17 (70.6%) |
| Treatment D: Oxycodone 30 mg and Buccal Placebo | 0/15 (0%) | 0/15 (0%) | 9/15 (60%) |
| Treatment E: Oxycodone 60 mg and Buccal Placebo | 0/16 (0%) | 0/16 (0%) | 14/16 (87.5%) |
| Treatment F: Oral Placebo and Buccal Placebo | 0/16 (0%) | 0/16 (0%) | 2/16 (12.5%) |
| Event | Treatment A: Belbuca 300 µg and Oral Placebo | Treatment B: Belbuca 600 µg and Oral Placebo | Treatment C: Belbuca 900 µg and Oral Placebo | Treatment D: Oxycodone 30 mg and Buccal Placebo | Treatment E: Oxycodone 60 mg and Buccal Placebo | Treatment F: Oral Placebo and Buccal Placebo |
|---|---|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 0/16 | 1/16 | 4/17 | 4/15 | 9/16 | 0/16 |
| SomnolenceNervous system disorders | 0/16 | 4/16 | 4/17 | 3/15 | 7/16 | 1/16 |
| VomitingGastrointestinal disorders | 1/16 | 1/16 | 4/17 | 2/15 | 6/16 | 0/16 |
| NauseaGastrointestinal disorders | 0/16 | 4/16 | 4/17 | 2/15 | 5/16 | 0/16 |
| Euphoric MoodPsychiatric disorders | 3/16 | 3/16 | 4/17 | 4/15 | 4/16 | 0/16 |
| DizzinessNervous system disorders | 1/16 | 4/16 | 2/17 | 1/15 | 2/16 | 0/16 |
| HeadacheNervous system disorders | 2/16 | 1/16 | 1/17 | 0/15 | 1/16 | 0/16 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 1/16 | 1/16 | 0/17 | 0/15 | 2/16 | 1/16 |
| Dry MouthGastrointestinal disorders | 0/16 | 0/16 | 1/17 | 1/15 | 1/16 | 0/16 |
| Feeling hotGeneral disorders | 0/16 | 0/16 | 0/17 | 1/15 | 1/16 | 0/16 |
| Age, Continuous(years) | All Arms |
|---|---|
| Mean | 33.1 ± 4.52 |
| Sex: Female, Male(Participants) | All Arms |
|---|---|
| Female | 1 |
| Male | 18 |
| Race (NIH/OMB)(Participants) | All Arms |
|---|---|
| American Indian or Alaska Native | 3 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 14 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2019 to primary completion in Oct 2019, 3 months.
Results were first posted in Feb 2021, 1 year 3 months after primary completion.
Of 12 phase 1 interventional studies under Respiratory Insufficiency, half reached primary completion within 11 months of starting (the median); a quarter within 3 and three quarters within 16. This study's 3 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Buprenorphine · Oxycodone
BioDelivery Sciences International